Interpretation: This Patient Has Clostridioides difficile Infection (CDI)
A positive C. difficile GDH antigen, negative toxin A/B immunoassay, and positive toxin B gene PCR indicates the presence of toxigenic C. difficile, and this patient should be treated for CDI based on current IDSA/SHEA guidelines and clinical context. 1
Algorithmic Interpretation
Your laboratory results follow a multistep diagnostic algorithm (GDH screening → toxin confirmation → PCR arbitration), which is the recommended approach per IDSA/SHEA 2017 guidelines 1:
Step-by-Step Result Analysis:
- GDH Antigen Positive = Screening test positive, indicating C. difficile organism present
- Toxin A/B Negative = Confirmatory test negative, creating discordance
- Toxin B Gene PCR Positive = Arbitration test positive, confirming toxigenic strain present
Clinical Significance and Treatment Decision
This result pattern indicates the patient harbors toxigenic C. difficile and should receive treatment if clinically appropriate (i.e., unexplained diarrhea ≥3 unformed stools in 24 hours). 1
Key Evidence Supporting Treatment:
The IDSA/SHEA guidelines specifically recommend using "GDH plus toxin, arbitrated by NAAT" as an acceptable diagnostic algorithm 1. When PCR is positive in this context, it confirms the presence of toxin genes (tcdB), indicating the organism has toxigenic capability.
However, critical nuance exists: The Polage et al. study found that toxin-negative/PCR-positive patients had significantly better outcomes than toxin-positive/PCR-positive patients:
- CDI-related complications: 0% vs 7.6% (P < .001) 1
- CDI-related mortality: minimal vs 8.4% 1
- Similar outcomes to patients negative by both tests 1
Risk Stratification Based on Your Results
Higher Risk Features (Treat More Aggressively):
- Low PCR cycle threshold (Ct) values (≤25-28 cycles) correlate with >90% likelihood of true toxin production 2
- Severe diarrhea (>6 stools/day, prolonged duration >2 days)
- Leukocytosis, renal insufficiency, hypoalbuminemia
- Recent antibiotic exposure 1
Lower Risk Features (Consider Colonization):
- High PCR Ct values (>28-30 cycles) suggest lower organism burden 3, 2
- Minimal diarrhea (<3 stools/day or <2 days duration)
- No systemic signs of infection
- Alternative explanation for diarrhea present 4
Practical Management Algorithm
If PCR Ct value available:
- Ct ≤25-28: Treat as CDI (>90% likelihood of toxin production) 2
- Ct >28-30: Individualize based on clinical severity; consider repeat toxin testing 3
If Ct value unavailable:
- Assess clinical severity using validated criteria
- Treat if moderate-severe symptoms present
- Consider repeat toxin testing in 24-48 hours if mild symptoms, as 4 initially toxin-negative samples became positive on repeat testing 5
Critical Pitfalls to Avoid
Don't dismiss PCR-positive/toxin-negative results entirely: While these patients have better outcomes on average, CDI-related complications can still occur 6
Sample handling matters: Frozen samples have reduced sensitivity for both GDH and toxin detection 7—if your sample was frozen, toxin negativity may be falsely negative
Don't over-treat colonization: 54-63% of GDH-positive/toxin-negative patients harbor toxigenic C. difficile 8, 5, but many represent colonization rather than active infection
Infection control implications: Even if you don't treat, this patient requires contact precautions as they shed toxigenic organisms and pose transmission risk 1
Strength of Evidence Assessment
The 2017 IDSA/SHEA guidelines 1 provide weak recommendation, low-quality evidence for multistep algorithms including NAAT. The 2019 ASM systematic review 9 supports this approach with high to moderate strength evidence for GDH-positive/toxin-negative followed by NAAT as best practice.
The most clinically relevant data comes from Polage et al., showing toxin-negative/PCR-positive patients have minimal CDI-related complications, suggesting many represent colonization rather than disease 1. However, this doesn't mean zero risk—clinical judgment remains essential.